Literature DB >> 12180111

Outpatient total body irradiation as a component of a comprehensive outpatient transplant program.

C Bredeson1, G Perry, C Martens, S McDiarmid, I Bence-Bruckler, H Atkins, D Serna, H Hopkins, J Mikhael, P Genest, L Huebsch.   

Abstract

Outpatient total body irradiation (TBI) as part of a comprehensive outpatient transplant program was delivered to 142 of 167 (85%) consecutive patients receiving TBI-based conditioning therapy. Outpatients received either a single fraction of 500 cGy (110 patients) or 1200 cGy in six fractions over 3 days (32 patients). Patients were assessed daily and were administered oral ondansetron and dexamethasone for prophylaxis of nausea and vomiting as well as i.v. hydration. Accommodation during outpatient TBI-based conditioning was either the patient's home if within 30 min of the hospital, a hotel on the hospital grounds or on a closed hospital ward. None of the 142 patients required admission to the inpatient program during their TBI. There was no difference in 100-day mortality between those receiving TBI as an outpatient (9%) vs as an inpatient (16%). Of four deaths occurring within the first 14 days post transplant, none could be attributed to receiving TBI as an outpatient. Two hundred and six inpatient days were saved through the delivery of outpatient TBI. A comprehensive outpatient program, appropriate patient selection, daily hydration, the use of prophylactic 5HT3 antagonist anti-emetic therapy all contribute to the safe delivery of outpatient TBI.

Entities:  

Mesh:

Year:  2002        PMID: 12180111     DOI: 10.1038/sj.bmt.1703516

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  1 in total

1.  Total Body Irradiation without Chemotherapy as Conditioning for an Allogeneic Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia.

Authors:  Sultan Altouri; Mitchell Sabloff; David Allan; Harry Atkins; Lothar Huebsch; Dawn Maze; Rajiv Samant; Christopher Bredeson
Journal:  Case Rep Hematol       Date:  2016-11-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.